Short answer
Revolution Medicines Inc (RVMD) filed an 8-K current report with the SEC on September 1, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 2.03 (Creation of a Direct Financial Obligation). New headquarters: 672,000 square feet across four Redwood City buildings, with staggered occupancy beginning September 2027.
Revolution Medicines Inc 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- New headquarters: 672,000 square feet across four Redwood City buildings, with staggered occupancy beginning September 2027
- Initial lease terms through September 2042, with three additional five-year extension options at fair market rent
- Full-commencement base rent approximately $2.7 million monthly, increasing approximately 3% annually
- Rent abatements through January 2030 total approximately $23.1 million; landlords provide approximately $115.9 million in tenant improvements
- Potential related-party transaction: Farallon owns approximately 6.4% of RVMD and indirectly controls a majority interest in the landlords
Item 2.03 · Creation of a Direct Financial Obligation
- Item 2.03 references Item 1.01 for the underlying lease-related financial obligations
- Potential future commitments tied to Phase II closing, leases, build-out, relocation and occupancy costs
- Timing and costs remain exposed to construction delays, permitting, landlord performance and changing space needs
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Revolution Medicines Inc 8-K filings
Get the next RVMD 8-K as it lands
Follow RVMD for push alerts, or ask the research agent what this filing means.